Evidence map›Paper›PMID 26116725›Full record

ArticleThe Journal of infectious diseases2015

Use of a 2-aminothiazole to Treat Chronic Wasting Disease in Transgenic Mice.

David Berry, Kurt Giles, Abby Oehler, Sumita Bhardwaj, Stephen J DeArmond, Stanley B Prusiner

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Adaptation of the protein misfolding cyclic amplification (PMCA) technique for the screening of anti-prion compounds.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Immunotherapy against Prion Disease.Pathogens (Basel, Switzerland) · 2020
    Review
  15. Article
  16. The role of prion strain diversity in the development of successful therapeutic treatments.Progress in molecular biology and translational science · 2020
    Review
  17. Molecular Mechanisms of Chronic Wasting Disease Prion Propagation.Cold Spring Harbor perspectives in medicine · 2018
    Review
  18. Developing Therapeutics for PrP Prion Diseases.Cold Spring Harbor perspectives in medicine · 2017
    Review
  19. Article
  20. Optimization of Aryl Amides that Extend Survival in Prion-Infected Mice.The Journal of pharmacology and experimental therapeutics · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

David BerryInstitute for Neurodegenerative Diseases.
Kurt GilesInstitute for Neurodegenerative Diseases Department of Neurology, University of California San Francisco.
Abby OehlerDepartment of Pathology.
Sumita BhardwajInstitute for Neurodegenerative Diseases.
Stephen J DeArmondInstitute for Neurodegenerative Diseases Department of Pathology.
Stanley B PrusinerInstitute for Neurodegenerative Diseases Department of Neurology, University of California San Francisco.
German Center for Neurodegenerative Diseases · DEUniversity of California, San Francisco · US

Funding

VIRAL DEGENERATIVE DEMENTING DISEASE IN AGING (SUPP)P01AG002132 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHNIER, PAUL · 1985 to 2024
$51.7M
UNDERSTANDING AND IMPROVING SMALL MOLECULE INHIBITORS OF PRION REPLICATIONP01AG021601 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 2003 to 2013
$31.9M
SYNTHETIC AND RECOMBINANT PRP PEPTIDES AND PROTEINSP01AG010770 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 1993 to 2015
$30.3M
Towards Therapeutics for Neurodegenerative DiseasesR37AG031220 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRUSINER, STANLEY B · 2008 to 2017
$6.2M
Identifying the Role of PrPSc Distribution & Other Proteins in Prion PathogenesisF32NS080630 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERRY, DAVID B · 2013 to 2015
$159k
NIA NIH HHS AG002132NIA NIH HHS AG010770NIA NIH HHS AG021601NIA NIH HHS AG031220NIA NIH HHS P01 AG002132NIA NIH HHS P01 AG010770NIA NIH HHS P01 AG021601NIA NIH HHS R37 AG031220NINDS NIH HHS F32 NS080630NINDS NIH HHS NS080630
6 · The paper itself

Abstract

Treatment with the 2-aminothiazole IND24 extended the survival of mice infected with mouse-adapted scrapie but also resulted in the emergence of a drug-resistant prion strain. Here, we determined whether IND24 extended the survival of transgenic mice infected with prions that caused scrapie in sheep or prions that caused chronic wasting disease (CWD; hereafter "CWD prions") in deer, using 2 isolates for each disease. IND24 doubled the incubation times for mice infected with CWD prions but had no effect on the survival of those infected with scrapie prions. Biochemical, neuropathologic, and cell culture analyses were used to characterize prion strain properties following treatment, and results indicated that the CWD prions were not altered by IND24, regardless of survival extension. These results suggest that IND24 may be a viable candidate for treating CWD in infected captive cervid populations and raise questions about why some prion strains develop drug resistance whereas others do not.

Indexed as

AnimalsBrainCell LineDeerDrug ResistanceFemaleKaplan-Meier EstimateMiceMice, TransgenicPrionsRabbitsScrapieSheepThiazolesWasting Disease, Chronic2-aminothiazolePrionsThiazoleschronic wasting diseaseprion diseasesurvival extensiontherapeutictransgenic mice

Identifiers

PMID26116725
PMCPMC4551108
OpenAlexW1945800197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.